Deletion of leucine zipper tumor suppressor 2 (Lzts2) increases susceptibility to tumor development.
By: Daniel T Johnson, Richard Luong, Suk Hyung Lee, Yue Peng, Atossa Shaltouki, Jane T Lee, Dong Lin, Yuzhuo Wang, Zijie Sun

Department of Urology, Stanford University School of Medicine, Stanford, California 94305-5328, USA.
2012-12-28; doi: 10.1074/jbc.M112.417568
Abstract

Using an Lzts2 knock-out mouse model, we characterized the biological role of Lzts2 in tumorigenesis. Both heterozygous and homozygous deletion of the Lzts2-targeted allele in mice shows an increased incidence in spontaneous tumor development, although Lzts2 homozygous knock-out mice show significantly higher incidences than heterozygous mice. Treatment of Lzts2-deficient mice with a carcinogen, N-butyl-N-(4-hydroxybutyl) nitrosamine, increases the susceptibility to N-butyl-N-(4-hydroxybutyl) nitrosamine-induced bladder carcinoma development. Examination of human prostate cancer tissue specimens shows a reduction of LZTS2 protein expression in prostate cancer cells. Further analyses of mouse embryonic fibroblasts isolated from Lzts2 knock-out embryos show that loss of Lzts2 enhances cell growth. These data provide the first line of evidence demonstrating that deletion of Lzts2 increases susceptibility to spontaneous and carcinogen-induced tumor development.





PMID:23275340






Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements